TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+6.18%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.03B
AUM Growth
+$2.03B
(+87%)
Cap. Flow
+$850M
Cap. Flow
% of AUM
41.76%
Top 10 Holdings %
Top 10 Hldgs %
48.77%
Holding
95
New
29
Increased
37
Reduced
1
Closed
2
Top Buys
| 1 |
Gilead Sciences
GILD
|
$105M |
| 2 |
CELG
Celgene Corp
CELG
|
$104M |
| 3 |
Pfizer
PFE
|
$46.3M |
| 4 |
Johnson & Johnson
JNJ
|
$34.9M |
| 5 |
AbbVie
ABBV
|
$27.8M |
Top Sells
| 1 |
FRX
FOREST LABORATORIES INC
FRX
|
$10.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$2.27M |
| 3 |
AEGR
Aegerion Pharmaceuticals, Inc.
AEGR
|
$1K |
Sector Composition
| 1 | Healthcare | 85.81% |
| 2 | Real Estate | 2.51% |
| 3 | Financials | 1.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$140B
| $265M | 12.43% | 2,490,531 +985,819 | +66% | +$105M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $193M | 9.05% | 2,036,434 +1,092,342 | +116% | +$104M |
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $78.8M | 3.7% | 701,944 +161,000 | +30% | +$18.1M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $74.9M | 3.51% | 451,905 +116,006 | +35% | +$19.2M |
|
5
Amgen
AMGN
$155B
| $71.6M | 3.36% | 510,042 +60,499 | +13% | +$8.5M |
|
|
6
Regeneron Pharmaceuticals
REGN
$61.5B
| $67.5M | 3.16% | 187,166 -6,300 | -3% | -$2.27M |
|
|
AGN
7
DELISTED
Allergan plc
AGN
| $67M | 3.14% | 277,631 +71,924 | +35% | +$17.4M |
|
8
Biogen
BIIB
$19.4B
| $61.8M | 2.9% | 186,783 +12,800 | +7% | +$4.23M |
|
|
9
Pfizer
PFE
$141B
| $56.2M | 2.64% | 1,902,241 +1,567,284 | +468% | +$46.3M |
|
10
Incyte
INCY
$16.5B
| $56M | 2.63% | 1,141,961 +373,723 | +49% | +$18.3M |
|
11
BioMarin Pharmaceuticals
BMRN
$11.2B
| $51.3M | 2.4% | 710,527 +289,143 | +69% | +$20.9M |
|
12
Viatris
VTRS
$12.3B
| $46M | 2.15% | 1,010,105 +357,896 | +55% | +$16.3M |
|
|
AGN
13
DELISTED
ALLERGAN INC
AGN
| $40.7M | 1.91% | 228,227 +71,600 | +46% | +$12.8M |
|
14
Illumina
ILMN
$15.8B
| $37.6M | 1.76% | 229,341 +125,500 | +121% | +$20.6M |
|
15
Teva Pharmaceuticals
TEVA
$21.1B
| $35.1M | 1.64% | 652,194 +340,718 | +109% | +$18.3M |
|
|
16
Johnson & Johnson
JNJ
$427B
| $34.9M | 1.63% | +327,212 | New | +$34.9M |
|
|
CBST
17
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $32.8M | 1.54% | 494,454 +230,682 | +87% | +$15.3M |
|
18
Thermo Fisher Scientific
TMO
$186B
| $32.5M | 1.52% | 266,875 +207,215 | +347% | +$25.2M |
|
|
SHPG
19
DELISTED
Shire pic
SHPG
| $31.9M | 1.5% | 123,322 | – | – |
|
|
AET
20
DELISTED
Aetna Inc
AET
| $31.5M | 1.48% | 389,031 +141,490 | +57% | +$11.5M |
|
21
Jazz Pharmaceuticals
JAZZ
$7.75B
| $27.8M | 1.3% | 173,241 +77,284 | +81% | +$12.4M |
|
|
22
AbbVie
ABBV
$372B
| $27.8M | 1.3% | +481,219 | New | +$27.8M |
|
23
Bristol-Myers Squibb
BMY
$96B
| $27.4M | 1.28% | 535,240 +332,640 | +164% | +$17M |
|
|
AKRX
24
DELISTED
Akorn, Inc.
AKRX
| $25.4M | 1.19% | 699,382 | – | – |
|
|
IPXL
25
DELISTED
Impax Laboratories, Inc.
IPXL
| $23.5M | 1.1% | 990,283 +645,600 | +187% | +$15.3M |
|